Balyasny Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-11
| Closed | -$418 | – | 2788 |
|
|
2022
Q4 | $418 | Sell |
11
-30,507
| -100% | -$1.16M | ﹤0.01% | 2274 |
|
|
2022
Q3 | $767K | Sell |
30,518
-66,080
| -68% | -$1.66M | ﹤0.01% | 1463 |
|
|
2022
Q2 | $2.94M | Buy |
96,598
+87,481
| +960% | +$2.66M | 0.01% | 969 |
|
|
2022
Q1 | $299K | Sell |
9,117
-135,404
| -94% | -$4.44M | ﹤0.01% | 1574 |
|
|
2021
Q4 | $3.81M | Buy |
+144,521
| New | +$3.81M | 0.01% | 797 |
|
|
2021
Q2 | – | Sell |
-108,809
| Closed | -$10.8M | – | 2182 |
|
|
2021
Q1 | $10.8M | Buy |
+108,809
| New | +$10.8M | 0.05% | 391 |
|
|
2020
Q4 | – | Sell |
-5,284
| Closed | -$515K | – | 1571 |
|
|
2020
Q3 | $515K | Buy |
+5,284
| New | +$515K | ﹤0.01% | 880 |
|
|
2020
Q2 | – | Sell |
-3,895
| Closed | -$562K | – | 1412 |
|
|
2020
Q1 | $562K | Buy |
+3,895
| New | +$562K | 0.01% | 758 |
|